Dosing recommendations for antiviral agents for prevention of influenza in children and adolescents^[1,2]

Drug/formulation	Dosing recommendations for prophylaxis
Oseltamivir (Tamiflu)* 30 mg capsule 45 mg capsule 75 mg capsule 6 mg/mL suspension^¶	1 through 12 years				≥13 years
	≤15 kg	>15 to 23 kg	>23 to 40 kg	>40 kg	75 mg orally once daily
	30 mg orally once daily	45 mg orally once daily	60 mg orally once daily	75 mg orally once daily
Zanamivir^Δ (Relenza) 5 mg per inhalation (Diskhaler)	Children ≥5 years and adults
	2 inhalations (10 mg total per dose)
Baloxavir (Xofluza) for postexposure prophylaxis^◊ 20 mg tablet 40 mg tablet 2 mg/mL suspension	Children ≥5 years and adults^§
	<20 kg (oral suspension) – 2 mg/kg single dose orally 20 to <80 kg (oral suspension or tablet) – 40 mg single dose orally ≥80 kg (oral suspension or tablet) – 80 mg single dose orally

This table is meant for use with UpToDate content related to chemoprophylaxis for seasonal influenza in children. The choice of agent for prophylaxis depends upon the age of the child, susceptibility patterns of circulating strains (if known), and concern about risk of emergent resistance. The duration of prophylaxis for oseltamivir and zanamivir varies with the clinical circumstances. Refer to UpToDate content for additional details, including indications for chemoprophylaxis and dosing recommendations for children younger than 1 year.

* Dose adjustment is necessary for patients with decreased or decreasing glomerular filtration rate.

¶ When dispensing the oral suspension of oseltamivir, pharmacists or other health care personnel should provide an oral syringe that can accurately measure the prescribed milliliter (mL) dose.

Δ Zanamivir inhalation powder should not be reconstituted in any liquid formulation and is not recommended for use in nebulizers or mechanical ventilators.

◊ Avoid administering baloxavir with milk, other dairy, antacids, or mineral supplements (eg calcium, iron, magnesium), which can significantly decrease oral bioavailability^[2].

§ Baloxavir is available in Japan for postexposure prophylaxis in children <12 years of age who weigh >20 kg. Refer to Japanese prescribing information for dosing information for children <12 years of age.

References:

American Academy of Pediatrics. Non-HIV antiviral drugs. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32^nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.930.
Xofluza (baloxavir marboxil). US Food and Drug Administration (FDA) approved product information. Revised August 2022. Available online at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (Accessed on August 16, 2022).

Graphic 61888 Version 22.0

خرید پکیج

Dosing recommendations for antiviral agents for prevention of influenza in children and adolescents[1,2]

Dosing recommendations for antiviral agents for prevention of influenza in children and adolescents^[1,2]